A Phase 2/3 Open-Label, Single-Arm Trial to Evaluate the Safety and Activity of Eculizumab in Pediatric Patients with Relapsing Neuromyelitis Optica Spectrum Disorder

Administered By

Awarded By

Contributors

Start/End

  • November 16, 2020 - November 30, 2022